NS Pharma, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1999-01-01

Employees: 51

Market Cap: -

Website: http://www.nspharma.com

Clinical Trials

NS-050/NCNP-03 in Boys With DMD (Meteor50)

Phase 1

Recruiting

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: NS-050/NCNP-03
Drug: Placebo

First Posted Date: 2023-09-26

Last Posted Date: 2024-12-17

Lead Sponsor: NS Pharma, Inc.

Target Recruit Count: 20

Registration Number: NCT06053814

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 8 locations

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

Phase 2

Recruiting

Conditions: Eosinophilic Granulomatosis With Polyangiitis
Churg-Strauss Syndrome

Interventions: Drug: NS-229
Drug: Placebo

First Posted Date: 2023-09-21

Last Posted Date: 2024-12-18

Lead Sponsor: NS Pharma, Inc.

Target Recruit Count: 45

Registration Number: NCT06046222

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇮🇹
Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy
🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan

and more 25 locations

NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

Phase 2

Recruiting

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: NS-089/NCNP-02

First Posted Date: 2023-08-16

Last Posted Date: 2024-11-01

Lead Sponsor: NS Pharma, Inc.

Target Recruit Count: 20

Registration Number: NCT05996003

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Rare Disease Research, Atlanta, Georgia, United States
🇺🇸
Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 6 locations

Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)

Phase 2

Completed

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: Viltolarsen

First Posted Date: 2021-07-09

Last Posted Date: 2024-08-20

Lead Sponsor: NS Pharma, Inc.

Target Recruit Count: 20

Registration Number: NCT04956289

Locations: 🇨🇳
The Third Medical Center of PLA General Hospital, Beijing, China
🇷🇺
Russian National Research Medical University, Moscow, Russian Federation
🇨🇳
Hunan Children's Hospital, Changsha, China

and more 5 locations

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Phase 2

Terminated

Conditions: Primary Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis

Interventions: Drug: NS-018
Drug: Best Available Therapy

First Posted Date: 2021-04-22

Last Posted Date: 2024-06-06

Lead Sponsor: NS Pharma, Inc.

Target Recruit Count: 7

Registration Number: NCT04854096

Locations: 🇺🇸
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇩🇪
Universitaetsklinikum Halle (Saale), Halle, Germany

and more 48 locations

Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

Phase 3

Active, not recruiting

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: Viltolarsen

First Posted Date: 2021-02-24

Last Posted Date: 2024-02-14

Lead Sponsor: NS Pharma, Inc.

Target Recruit Count: 74

Registration Number: NCT04768062

Locations: 🇦🇺
Queensland Children's Hospital, Brisbane, Australia
🇬🇧
Birmingham Heartlands Hospital, Birmingham, United Kingdom
🇬🇧
Royal Hospital for Children, Glasgow, United Kingdom

and more 28 locations

Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)

Phase 4

Active, not recruiting

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: Viltolarsen

First Posted Date: 2020-12-29

Last Posted Date: 2022-10-19

Lead Sponsor: NS Pharma, Inc.

Target Recruit Count: 9

Registration Number: NCT04687020

Locations: 🇨🇦
Alberta Children's Hospital, Calgary, Alberta, Canada
🇺🇸
Lurie Children's Hospital, Chicago, Illinois, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 2 locations

The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation

Conditions: Muscular Dystrophy, Duchenne
DMD

First Posted Date: 2020-04-07

Last Posted Date: 2020-08-18

Lead Sponsor: NS Pharma, Inc.

Registration Number: NCT04337112

Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)

Phase 3

Completed

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: Placebo
Drug: Viltolarsen

First Posted Date: 2019-08-19

Last Posted Date: 2024-12-11

Lead Sponsor: NS Pharma, Inc.

Target Recruit Count: 77

Registration Number: NCT04060199

Locations: 🇦🇺
The Childrens Hospital at Westmead, Westmead, Australia
🇬🇧
Birmingham Heartlands Hospital, Birmingham, United Kingdom
🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan

and more 37 locations

Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

Phase 2

Completed

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: NS-065/NCNP-01

First Posted Date: 2017-05-25

Last Posted Date: 2022-12-28

Lead Sponsor: NS Pharma, Inc.

Target Recruit Count: 16

Registration Number: NCT03167255

Locations: 🇺🇸
Lurie Children's Hospital, Chicago, Illinois, United States
🇺🇸
Washington University, Saint Louis, Missouri, United States
🇨🇦
Alberta Children's Hospital, Calgary, Alberta, Canada

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy